Published in J Virol on June 30, 2010
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol (2012) 1.14
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog (2014) 1.07
The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J Virol (2011) 1.04
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog (2013) 0.98
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem (2010) 0.97
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3. J Immunol (2013) 0.90
Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology (2013) 0.87
Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog (2014) 0.87
Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology (2013) 0.80
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. PLoS One (2014) 0.80
Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections. J Virol (2014) 0.79
Long-term passage of Vif-null HIV-1 in CD4(+) T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance. Virology (2017) 0.75
Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLoS Genet (2016) 0.75
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology (2005) 2.84
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology (2006) 1.86
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol (2008) 1.83
Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J (2006) 1.64
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol (2008) 1.21
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol (2002) 1.06
Biased G-to-A hypermutation in HIV-1 proviral DNA from a long-term non-progressor. AIDS (2004) 1.01
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health (2007) 3.18
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog (2011) 2.65
Male involvement in PMTCT services in Mbeya Region, Tanzania. AIDS Behav (2009) 2.59
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83
DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog (2012) 1.80
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr (2006) 1.66
Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS One (2011) 1.59
Strabismus and discrimination in children: are children with strabismus invited to fewer birthday parties? Br J Ophthalmol (2010) 1.55
In vitro evidence that the untranslated leader of the HIV-1 genome is an RNA checkpoint that regulates multiple functions through conformational changes. J Biol Chem (2002) 1.48
Human papillomavirus genome variants. Virology (2013) 1.45
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A (2011) 1.42
The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36
Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology (2006) 1.34
Recent developments in pain in dementia. BMJ (2005) 1.33
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 1.30
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol (2011) 1.25
Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog (2013) 1.20
HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol (2014) 1.19
Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.19
Wanted: women in clinical trials. Science (2005) 1.17
APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol (2012) 1.14
Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Pannonica Adriat (2011) 1.14
The cervical microbiome over 7 years and a comparison of methodologies for its characterization. PLoS One (2012) 1.11
HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe (2013) 1.07
A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J Virol (2013) 1.07
The effect of depression on social engagement in newly admitted Dutch nursing home residents. Gerontologist (2003) 1.05
Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol (2002) 1.05
The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J Virol (2010) 1.05
APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog (2013) 0.98
Destabilization of the TAR hairpin affects the structure and function of the HIV-1 leader RNA. Nucleic Acids Res (2008) 0.94
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. J Virol (2007) 0.92
Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. Retrovirology (2008) 0.92
The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: a randomized clinical trial. Int J Geriatr Psychiatry (2005) 0.91
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. PLoS One (2012) 0.90
Immune mechanisms of HIV control. Curr Opin Immunol (2010) 0.89
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS (2010) 0.89
Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G. J Virol (2013) 0.88
Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB. Retrovirology (2014) 0.87
The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLoS One (2013) 0.86
Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother (2009) 0.86
Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One (2011) 0.84
Minor histocompatibility antigens are expressed in syncytiotrophoblast and trophoblast debris: implications for maternal alloreactivity to the fetus. Am J Pathol (2011) 0.84
Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS One (2013) 0.83
Identification and functional analysis of a second RBF-2 binding site within the HIV-1 promoter. Virology (2011) 0.83
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis. Antivir Ther (2011) 0.83
The perception of strabismus by children and adults. Graefes Arch Clin Exp Ophthalmol (2010) 0.82
Characterization of HIV-1 integrase N-terminal mutant viruses. Virology (2006) 0.82
Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother. Antivir Ther (2005) 0.82
HIV-1 interacts with human endogenous retrovirus K (HML-2) envelopes derived from human primary lymphocytes. J Virol (2014) 0.82
[Three new observational scales for use in Dutch nursing homes: scales from the Resident Assessment Instrument for Activities of Daily Living, cognition and depression]. Tijdschr Gerontol Geriatr (2004) 0.82
Balancing selection on a regulatory region exhibiting ancient variation that predates human-neandertal divergence. PLoS Genet (2013) 0.81
Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. J Clin Pharmacol (2013) 0.79
HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int J Cancer (2014) 0.79
Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda. MedGenMed (2006) 0.78
Outcome of Different Nevirapine Administration Strategies in Preventin g Mother-to-Child Transmission (PMTCT) Programs in Tanzania and Uganda. J Int AIDS Soc (2006) 0.77
Stimulus parameters for goldmann kinetic perimetry in nonorganic visual loss. Ophthalmologica (2009) 0.77
Effects of moxifloxacin and clinafloxacin on murine limb buds cultured in regular and in magnesium-deficient medium. Arch Toxicol (2009) 0.75
Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. AIDS (2016) 0.75
Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis. AIDS (2003) 0.75
[Whether or not to treat pneumonia curatively in (demented) psychogeriatric patients: evaluation of a guideline for nursing home physicians]. Tijdschr Gerontol Geriatr (2002) 0.75
Correction: Hepatitis C Virus Sensing by Human Trophoblasts Induces Innate Immune Responses and Recruitment of Maternal NK Cells: Potential Implications for Limiting Vertical Transmission. J Immunol (2017) 0.75
Intraoperative conversion rate to a large, limbal opening in minimally invasive strabismus surgery (MISS). Graefes Arch Clin Exp Ophthalmol (2011) 0.75